$445 M

RUBY Mkt cap, 18-Sept-2020
Rubius Therapeutics Net income (Q2, 2020)-37.9 M
Rubius Therapeutics EBIT (Q2, 2020)-37.7 M
Rubius Therapeutics Cash, 30-Jun-2020129.2 M
Rubius Therapeutics EV434.8 M

Rubius Therapeutics Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

R&D expense

8.4m21.2m51.8m112.4m

General and administrative expense

2.4m22.0m39.9m57.2m

Operating expense total

10.9m43.3m91.7m169.6m

EBIT

(10.9m)(43.3m)(91.7m)(169.6m)

Interest expense

149.0k309.0k2.5m

Interest income

8.0m

Net Income

(11.0m)(43.8m)(89.2m)(163.5m)

Rubius Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

6.8m104.3m307.1m91.9m

Prepaid Expenses

53.0k700.0k

Current Assets

6.9m105.0m414.4m289.3m

PP&E

868.0k2.4m62.8m56.9m

Total Assets

8.0m107.7m479.1m394.8m

Accounts Payable

1.2m2.0m7.9m7.2m

Short-term debt

9.3m2.1m10.5m

Current Liabilities

2.9m7.2m20.0m33.8m

Long-term debt

3.0m7.3m65.8m86.5m

Total Debt

12.3m9.4m65.8m97.0m

Total Liabilities

6.0m11.6m86.1m120.6m

Common Stock

8.0k15.0k79.0k80.0k

Preferred Stock

19.1m139.8m

Additional Paid-in Capital

17.3m543.0m586.8m

Retained Earnings

(17.1m)(61.0m)(150.1m)(312.7m)

Total Equity

1.9m96.1m393.0m274.2m

Debt to Equity Ratio

6.3 x0.1 x

Debt to Assets Ratio

1.5 x0.1 x

Financial Leverage

4.1 x1.1 x1.2 x1.4 x

Quarterly

USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

136.5m116.9m354.8m192.5m141.1m109.6m144.5m129.2m

Prepaid Expenses

838.0k

Current Assets

193.6m182.8m412.5m385.8m366.6m329.8m245.9m244.1m

PP&E

14.3m21.1m39.2m24.6m41.9m52.5m56.4m55.6m

Total Assets

209.7m207.5m452.8m441.5m438.0m432.3m348.3m344.4m

Accounts Payable

2.9m7.0m4.5m10.2m2.3m11.7m7.6m9.8m

Short-term debt

3.1m2.4m3.4m9.4m9.5m

Current Liabilities

11.3m14.9m16.0m20.7m21.2m33.5m27.4m28.9m

Long-term debt

2.5m19.6m25.5m48.5m72.6m90.9m85.4m109.4m

Total Debt

5.6m306.0k1.2m48.5m72.6m90.9m94.9m118.9m

Total Liabilities

24.5m37.5m41.8m69.8m94.4m124.9m113.2m139.0m

Common Stock

15.0k15.0k79.0k80.0k80.0k80.0k80.0k80.0k

Preferred Stock

240.8m

Additional Paid-in Capital

20.7m34.6m533.8m553.3m564.5m575.4m595.8m604.3m

Retained Earnings

(76.2m)(105.3m)(122.9m)(181.9m)(221.3m)(268.3m)(361.2m)(399.1m)

Total Equity

185.3m(70.7m)411.0m371.6m343.6m307.3m235.2m205.5m

Debt to Equity Ratio

0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x

Financial Leverage

1.1 x-2.9 x1.1 x1.2 x1.3 x1.4 x1.5 x1.7 x

Rubius Therapeutics Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(11.0m)(43.8m)(89.2m)(163.5m)

Depreciation and Amortization

118.0k447.0k1.3m3.0m

Accounts Payable

589.0k1.1m4.9m(1.0m)

Cash From Operating Activities

(9.5m)(21.9m)(58.3m)(110.4m)

Purchases of PP&E

(443.0k)(2.3m)(15.0m)(40.7m)

Cash From Investing Activities

(443.0k)(2.3m)(111.6m)(132.6m)

Long-term Borrowings

(5.5m)

Cash From Financing Activities

15.4m121.7m374.8m27.3m

Net Change in Cash

5.5m97.5m204.8m(215.8m)

Interest Paid

385.0k3.0m

Quarterly

USDQ1, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(4.9m)(15.3m)(44.4m)(62.0m)(32.6m)(72.0m)(119.0m)

Depreciation and Amortization

48.0k227.0k502.0k879.0k661.0k1.4m2.3m1.8m3.6m

Accounts Payable

937.0k452.0k3.0m2.4m(966.0k)(4.7m)3.2m905.0k3.1m

Cash From Operating Activities

(3.1m)(10.9m)(20.8m)(38.6m)(22.9m)(52.7m)(81.5m)(40.0m)(68.6m)

Purchases of PP&E

(271.0k)(830.0k)(1.5m)(11.7m)(4.2m)(17.4m)(27.4m)(2.9m)(3.9m)

Cash From Investing Activities

(271.0k)(57.0m)(66.2m)(65.6m)(93.0m)(140.1m)(143.3m)92.1m80.1m

Cash From Financing Activities

28.0k101.0m100.5m355.7m799.0k26.4m26.7m486.0k25.7m

Net Change in Cash

(3.3m)33.1m13.6m251.4m(115.1m)(166.5m)(198.1m)52.6m37.3m

Interest Paid

336.0k1.0m1.7m895.0k1.7m

Rubius Therapeutics Ratios

USDFY, 2016

Debt/Equity

6.3 x

Debt/Assets

1.5 x

Financial Leverage

4.1 x